Share on LinkedInShare on LinkedIn

ARTICLE · 19 JULY 2021

Patent Examination Guidelines – Inventive Step Of A Monoclonal Antibody

CCPIT Patent and Trademark Law Office
CCPIT Patent and Trademark Law Office
Contributor
CCPIT Patent and Trademark Law Office

CCPIT Patent and Trademark Law Office

CCPIT Patent and Trademark Law Office is the oldest and one of the largest full-service...

View firm profile
Explore more from CCPIT Patent and Trademark Law Office

In biopharmaceuticals, an antibody patent is one of the most valuable patents in the field.

ChinaIntellectual Property

In biopharmaceuticals, an antibody patent is one of the most valuable patents in the field. A claimed monoclonal antibody (see Table 1) can be defined as:

  • an antigen or an epitope on an antigen to which the antibody is directed;
  • a hybridoma producing the antibody; or
  • amino acid sequences constituting the antibody.

It is preferable if the antigen to be directed by the claimed antibody is a novel and inventive one. If it is novel and inventive, a monoclonal antibody patent can be defined directly by the antigen and a patent claim with the broadest scope can be granted. If it is not novel and inventive, although an antibody can still be claimed by a hybridoma

producing the antibody or amino acid sequences constituting the antibody, it will be unclear whether such a defined antibody can be considered to be inventive enough (see Table 2).

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from